Literature DB >> 9876544

Physicochemical stability of crystalline sugars and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers.

V Naini1, P R Byron, E M Phillips.   

Abstract

Lactose, trehalose, sucrose, and mannitol were purchased in crystalline form and fractionated by sieving. Coarse (125-212 microns) and fine (44-74 microns) free-flowing fractions were selected as typical of drug carriers in dry-powder inhalers. In addition, one batch of each sugar was spray-dried to form a respirable powder (> 50% [w/w], < 5 microns). Both fractions and the spray-dried powders were characterized before and after storage for 30 days at < 23%, 23%, 52%, 75% and 93% relative humidity (RH) at 25 degrees C. Moisture uptake was determined by thermogravimetric analysis (TGA) validated by Karl Fischer titration. Sieve fractions (before storage at different RHs) and spray-dried materials (before and after storage) were further characterized by differential scanning calorimetry (DSC) and x-ray powder diffraction (XRPD). All crystalline sieve fractions (except sucrose at 93% RH) were stable at 25 degrees C and showed insignificant moisture uptake when exposed to each relative humidity for 30 days. Sucrose dissolved in sorbed moisture at 93% RH. Spray-dried lactose, sucrose, and trehalose, which were collected in the amorphous form, showed moisture uptake, without recrystallization, when held for 30 days at 23% RH. These sugars recrystallized as sintered masses and became undispersible at > or = 52% RH. Spray-dried mannitol was apparently 100% crystalline when collected directly from the spray-dryer; it did not show humidity-induced changes. The physicochemical behavior of each sugar form is discussed as it relates to the sugar's suitability as a powder-inhaler excipient, with both conventional and protein drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876544     DOI: 10.3109/03639049809097269

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

1.  Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.

Authors:  Tobias W M Keil; Daniel P Feldmann; Gabriella Costabile; Qian Zhong; Sandro da Rocha; Olivia M Merkel
Journal:  Eur J Pharm Biopharm       Date:  2019-08-21       Impact factor: 5.571

2.  Physicochemical properties of amorphous roxithromycin prepared by quench cooling of the melt or desolvation of a chloroform solvate.

Authors:  Marique Aucamp; Wilna Liebenberg; Schalk J Strydom; Elsa C van Tonder; Melgardt M de Villiers
Journal:  AAPS PharmSciTech       Date:  2012-03-06       Impact factor: 3.246

3.  Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.

Authors:  Nivedita Shetty; Heejun Park; Dmitry Zemlyanov; Sharad Mangal; Sonal Bhujbal; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-04-18       Impact factor: 5.875

4.  Stable dry powder formulation for nasal delivery of anthrax vaccine.

Authors:  Sheena H Wang; Shaun M Kirwan; Soman N Abraham; Herman F Staats; Anthony J Hickey
Journal:  J Pharm Sci       Date:  2011-09-08       Impact factor: 3.534

5.  Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying.

Authors:  Donglei Leng; Kaushik Thanki; Camilla Foged; Mingshi Yang
Journal:  Pharm Res       Date:  2018-11-01       Impact factor: 4.200

6.  Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery.

Authors:  Susan Hoe; James W Ivey; Mohammed A Boraey; Abouzar Shamsaddini-Shahrbabak; Emadeddin Javaheri; Sadaf Matinkhoo; Warren H Finlay; Reinhard Vehring
Journal:  Pharm Res       Date:  2013-08-23       Impact factor: 4.200

7.  Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy.

Authors:  Zitong Shao; Waiting Tai; Yingshan Qiu; Rico C H Man; Qiuying Liao; Michael Y T Chow; Philip C L Kwok; Jenny K W Lam
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.